Identification and treatment of individuals at high risk of coronary heart disease

American Journal of Medicine

Volumn 112, Issue 8 SUPPL. 1, 2002, Pages 3-9

  Stein, Evan A ^a,b  

^a Metabolic and Atherosclerosis Research Center   (United States)

^b Pharmaceutical Product Development   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (3,4 DIMETHOXYPHENYL) 3 (3 ETHYLVALERYL) 4 HYDROXY 6,7,8 TRIMETHOXY 2 NAPHTHOIC ACID METHYL ESTER; ANTILIPEMIC AGENT; ATORVASTATIN; CERIVASTATIN; EZETIMIBE; FLUINDOSTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; NICOTINIC ACID; PITAVASTATIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; STANOL ESTER; UNCLASSIFIED DRUG;

ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL FEATURE; CLINICAL TRIAL; DIABETES MELLITUS; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; FAMILIAL HYPERCHOLESTEROLEMIA; HIGH RISK POPULATION; HUMAN; ISCHEMIC HEART DISEASE; MONOTHERAPY; MORBIDITY; MORTALITY; PRIORITY JOURNAL; REVIEW;

EID: 0037014053     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0002-9343(02)01084-7     Document Type: Review

References (30)

1. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia
2. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. Results of AFCAPS/TexCAPS
3. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
4. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels
5. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels
6. Maximizing the cost-effectiveness of lipid-lowering therapy
7. Ten-year mortality from cardiovascular disease in relation to cholesterol level among men with and without preexisting cardiovascular disease
8. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S)
9. Risks of ischaemic heart-disease in familial hyperlipoproteinaemic states
10. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)
11. Management of dyslipidemia in adults with diabetes
12. Recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention
13. National Cholesterol Education Program (NCEP). Summary of the Second Report of the Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)
14. The Lipid Treatment Assessment Project (L-TAP). A multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals
15. Analysis of the degree of undertreatment of hyperlipidemia and congestive heart failure secondary to coronary artery disease
16. Drug treatment of lipid disorders
17. New statins and new doses of older statins
18. The rule of 5 and 7 in lipid-lowering by statin drugs
19. Effects of simvastatin and cholestyramine in familial and nonfamilial hypercholesterolemia
20. Randomised controlled trial of use by hypercholesterolaemic patients of a vegetable oil sterol-enriched fat spread
21. New combination niacin/statin formulation shows pronounced effects on major lipoproteins and is well tolerated
22. Long term effects of NK-104 (pitavastatin) a new HMG CoA reductase inhibitor in patients with heterozygous familial hypercholesterolemia
23. Effect of rosuvastatin on low-density lipoprotein cholesterol in patients with hypercholesterolemia
24. ZD4522 is superior to atorvastatin in decreasing low density lipoprotein cholesterol and increasing high density lipoprotein cholesterol in patients with type IIa or IIb hypercholesterolemia
25. ZD4522 is superior to pravastatin and simvastatin in reducing low density lipoprotein cholesterol, enabling more hypercholesterolemic patients to achieve target low density lipoprotein cholesterol guidelines
26. ZD4522 is superior to atorvastatin in the treatment of patients with heterozygous familial hypercholesterolemia
27. +/bile acid cotransporter by S-8921 reduces serum cholesterol and prevents atherosclerosis in rabbits
28. A target for cholesterol absorption inhibitors in the enterocyte brush border membrane
29. Reduction of LDL-cholesterol and elevation of HDL-cholesterol in subjects with primary hypercholesterolemia by SCH 58235: Pooled analysis of two phase II studies
30. Pharmacodynamic interaction between the new selective cholesterol absorption inhibitor ezetimibe and simvastatin